Galena Biopharma Inc  

(Public, NASDAQ:GALE)   Watch this stock  
Find more results for GALE
1.90
+0.01 (0.53%)
Oct 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.83 - 1.94
52 week 1.56 - 7.77
Open 1.89
Vol / Avg. 856,680.00/1.51M
Mkt cap 223.41M
P/E     -
Div/yield     -
EPS -0.75
Shares 118.21M
Beta 1.19
Inst. own 19%
Dec 10, 2014
Galena Biopharma Inc at Oppenheimer Healthcare Conference Add to calendar
Nov 6, 2014
Q3 2014 Galena Biopharma Inc Earnings Release - 4:00PM EST - Add to calendar
Sep 25, 2014
Galena Biopharma Inc Announces Release of Special Committee Report and Provides Abstral� (fentanyl) and NeuVaxT (nelipepimut-S) Enrollment Updates
Sep 9, 2014
Galena Biopharma Inc at Rodman & Renshaw Global Investment Conference
Aug 11, 2014
Q2 2014 Galena Biopharma Inc Earnings Call
Aug 11, 2014
Q2 2014 Galena Biopharma Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -855.47% -3083.15%
Operating margin -698.11% -1397.91%
EBITD margin - -1342.50%
Return on average assets -92.70% -107.27%
Return on average equity -213.82% -455.85%
Employees 60 -
CDP Score - -

Address

SUITE 270, 4640 SW MACADAM AVENUE
PORTLAND, OR 97239
United States - Map
+1-855-8554253 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin; Genentech/Roche). In January 2014, Galena Biopharma Inc acquired Mills Pharmaceuticals, which has the worldwide rights to GALE-401 (Anagrelide CR), a patented, controlled release formulation of anagrelide.

Officers and directors

Sanford J. Hillsberg J.D. Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Mark W. Schwartz Ph.D. President, Chief Executive Officer
Age: 58
Bio & Compensation  - Reuters
Ryan M. Dunlap Chief Financial Officer, Vice President, Secretary
Age: 44
Bio & Compensation  - Reuters
Brian L. Hamilton M.D. Ph.D. Executive Vice President and Chief Medical Officer
Age: 66
Bio & Compensation  - Reuters
Irving M. Einhorn Director
Age: 72
Bio & Compensation  - Reuters
William L. Ashton Independent Director
Age: 63
Bio & Compensation  - Reuters
Richard H. Chin M.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Stephen S. Galliker CPA Independent Director
Age: 67
Bio & Compensation  - Reuters
Steven A. Kriegsman Independent Director
Age: 72
Bio & Compensation  - Reuters